COVID cases and hospitalisations have risen sharply in the UK over the past week, with two new variants gaining momentum. It comes as millions of Brits have just two days to get their Covid booster…
"We can expect further increases in transmission and hospitalisations in future weeks," Dr Mary added.The Joint Committee on Vaccination and Immunisation , which advised ministers on the latest move, said the vaccine rollout should now become “more targeted”.
If your NHS record shows you're at high risk from Covid-19, you should be invited for a seasonal booster. You can have your seasonal booster if it's been at least three months since you had your previous dose, guidance states. If you have not had a first or second dose of the Covid-19 vaccine yet, you should have them as soon as possible, the NHS states.
If you have a severely weakened immune system you should get an additional primary dose before you get a booster.A high temperature - once one of the most prevalent Covid symptoms - has fallen of the top 20 list of symptoms for the first time, according to data from the
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Acute phase characteristics and long-term complications of pulmonary embolism in COVID-19 compared to non-COVID-19 cohort: a large single-centre study - BMC Pulmonary MedicineBackground To compare the severity of pulmonary embolism (PE) and the long-term complications between patients with and without COVID-19, and to investigate whether the tools for risk stratification of death are valid in this population. Methods We retrospectively included hospitalized patients with PE from 1 January 2016 to 31 December 2022. Comparisons for acute episode characteristics, risk stratification of the PE, outcomes, and long-term complications were made between COVID and non-COVID patients. Results We analyzed 116 (27.5%) COVID patients and 305 (72.4%) non-COVID patients. In patients with COVID-19, the traditional risk factors for PE were absent, and the incidence of deep vein thrombosis was lower. COVID patients showed significantly higher lymphocyte count, lactate dehydrogenase, lactic acid, and D-dimer levels. COVID patients had PE of smaller size (12.3% vs. 25.5% main pulmonary artery, 29.8% vs. 37.1% lobar, 44.7% vs. 29.5% segmental and 13.2% vs. 7.9% subsegmental, respectively; p | 0.001), less right ventricular dysfunction (7.7% vs. 17.7%; p = 0.007) and higher sPESI score (1.66 vs. 1.11; p | 0.001). The need for mechanical ventilation was significantly higher in COVID patients (8.6% vs. 1.3%; p | 0.001); However, the in-hospital death was less (5.2% vs. 10.8%; p = 0.074). The incidence of long-term complications was lower in COVID cohort (p | 0.001). PE severity assessed by high sPESI and intermediate and high-risk categories were independently associated with in-hospital mortality in COVID patients. Conclusion The risk of in-hospital mortality and the incidence of long-term complications were lower in COVID-19. The usual tools for risk stratification of PE are valid in COVID patients.
Read more »
China's COVID surge produced no new variants, analysis suggestsChina bringing its zero COVID policy to an end led to a spike in cases late last year, fuelling fears that a new variant could emerge.
Read more »
No new SARS-CoV-2 variants detected in China since COVID policy changeIn a recent study published in The Lancet, researchers reported the trends in coronavirus disease 2019 (COVID-19) cases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in Beijing in 2022.
Read more »